Online inquiry

IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9730MR)

This product GTTS-WQ9730MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD3E&GPRC5D gene. The antibody can be applied in Relapsed multiple myeloma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_018654.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 55507
UniProt ID P07766; Q9NZD1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ9730MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5862MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ9112MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMGN242
GTTS-WQ2232MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aVWF81
GTTS-WQ14938MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ7326MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA FPA-144
GTTS-WQ15049MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ14863MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ11590MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MGAH-22
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW